News & Events about Stockal+Disclaimer.pdf.
Business Wire
11 months ago
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted marketing authorization of LUPKYNIS (voclosporin) in combination with a background immunosuppressive therapy to treat adults with active class...
Business Wire
11 months ago
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that Glass Lewis & Co. (Glass Lewis), a leading independent proxy advisor, has recommended that Aurinia shareholders vote FOR ALL proposals at the Companys 2023 Annual General Meeting (the Meeting...
Business Wire
12 months ago
Toni Braxton, the award-winning singer, songwriter, actress, producer, and entrepreneur is speaking out about living with lupus and the importance of prioritizing kidney health. In partnership with Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), a biopharmaceutical company committed to changing the...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the United States Patent and Trademark Office (USPTO) has issued a new and refined method of use patent titled IMPROVED PROTOCOL FOR TREATMENT OF LUPUS NEPHRITIS. Aurinias newly issued U.S. Patent (No...
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH Get Rating) (TSX:AUP) has earned an average recommendation of Moderate Buy from the six analysts that are currently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating and four have assigned a buy ...